Abstract
The use of combination antiretroviral therapy (ART) has transformed HIV infection from a fatal illness into a chronic disease. As a consequence, the long-term cardiopulmonary complications, including HIV-associated pulmonary arterial hypertension, have emerged as the primary source of morbidity and mortality, representing an important health-care concern.1 HIV-associated pulmonary arterial hypertension is a life-threatening condition characterised by pulmonary vascular remodelling, elevated pulmonary arterial pressure, and right heart failure.
Highlights
The use of combination antiretroviral therapy (ART) has transformed HIV infection from a fatal illness into a chronic disease
HIV-associated pulmonary arterial hypertension is a life-threatening condition characterised by pulmonary vascular re modelling, elevated pulmonary arterial pressure, and right heart failure
In the Lancet Healthy Longevity, Meredith S Duncan and colleagues[4] used data from Veterans Aging Cohort Study (VACS) participants referred for a clinical echocardiogram in whom estimated pulmonary artery systolic pressure (PASP) was reported
Summary
The use of combination antiretroviral therapy (ART) has transformed HIV infection from a fatal illness into a chronic disease. It has been suggested that people living with HIV have a higher incidence of pulmonary hypertension than the general population.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
